Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Postoperative adjuvant TACE + anti-PD-1 with or without donafenib in high-risk hepatocellular carcinoma
ChiCTR2600133654Phase 4Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of donafenib in hepatocellular carcinoma (HCC) and liver cancer (3 arms), sponsored by Tongji Hospital. Primary endpoint: 1-year recurrence-free survival rate. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
donafenib
03
Conditions
hepatocellular carcinoma (HCC)liver cancer
Beyond the preview
Go deeper on ChiCTR2600133654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600133654.